mTOR Inhibition by Everolimus Does Not Impair Closure of Punch Biopsy Wounds in Renal Transplant Patients

BACKGROUND: Mammalian target of rapamycin (mTOR) inhibitors are approved to prevent allograft rejection and control malignancy. Unfortunately, they are associated with adverse effects, such as wound healing complications that detract from more extensive use. There is a lack of prospective wound heal...

Descripción completa

Detalles Bibliográficos
Autores principales: Dutt, Shelley B., Gonzales, Josephine, Boyett, Megan, Costanzo, Anne, Han, Peggy P., Steinberg, Steven, McKay, Dianne B., Jameson, Julie M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2017
Materias:
Kidney Transplantation
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5381740/
https://www.ncbi.nlm.nih.gov/pubmed/28405603
http://dx.doi.org/10.1097/TXD.0000000000000663

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5381740/
https://www.ncbi.nlm.nih.gov/pubmed/28405603
http://dx.doi.org/10.1097/TXD.0000000000000663

Ejemplares similares